LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

NCT01345669 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

617

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

DRUG: Placebo
DRUG: Afatinib

Sponsor

Boehringer Ingelheim